Project Grant R01HL179818
Award Date 7/10/25
Completion Date 4/30/29
Dollars Obligated $730K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This $1,082,412 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research and development of tissue-engineered vascular grafts (TEVGs) using mesenchymal stem/stromal cells (MSCs) and extracellular vesicles (EVs). The University of Pittsburgh, the awardee, aims to optimize their silk scaffold-based TEVG construct seeded with EVs to advance it towards clinical translation. Key objectives include conducting in vitro...
- This $590,283 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop feedback-controlled closed-loop manufacturing processes for differentiating human pluripotent stem cells into cardiomyocytes. The key objectives are to: 1) Identify failure modes in 2D cardiomyocyte differentiation through integrated single-cell transcriptomics and epigenomics, and 2) Develop control strategies to enhance the reproducibility of human...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...
- The federal Project Grant award, titled "Intravenously Injected Mesenchymal Stromal Cells Protect Against Acute Lung Injury by Transferring Mitochondria to Restore Endothelial Function", was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $761,262 award, granted on Sep 1, 2025, supports research to define the mechanisms by which bone marrow-derived mesenchymal stromal cells (BMSCs) can protect against...
- The federal Project Grant award titled "NICHE-SPECIFIC ENDOTHELIAL MECHANISMS REGULATING THE EXTRAVASATION OF HEMATOPOIETIC STEM CELLS" is funded by the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837). The $734,607 award, effective May 1, 2025 through February 28, 2030, supports research at Boston Medical Center Corporation to elucidate the key endothelial mechanisms that direct circulating hematopoietic stem cells across the...
- The federal Project Grant award of $507,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop an automated system that integrates micro-electromechanical sensors, automation, and machine vision to simultaneously measure electrophysiological properties and contractile forces in single human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). This innovative system is expected to significantly reduce measurement time...
- The National Heart, Lung, and Blood Institute awarded a $989,908 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nevada, Las Vegas (UNLV) to investigate the use of Wnt11-treated mesenchymal stem cells (MSCs) for improving cardiac repair after myocardial infarction. The 4-year project aims to examine if Wnt11 treatment can enhance MSC retention, survival, and reparative effects in vitro and in a mouse model of reperfused myocardial infarction....
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- The National Heart, Lung, and Blood Institute, through the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $697,296 project grant to The Trustees of Columbia University in the City of New York, Health Sciences Division, to investigate the role of N6-methyladenosine (m6A) epitranscriptomic mRNA modification in the generation and regeneration of the hematopoietic stem cell (HSC) niche within the bone marrow. This 4-year project aims to characterize how m6A regulates the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...